Skip to content
Livtencity(maribavir)
Livtencity (maribavir) is a small molecule pharmaceutical. Maribavir was first approved as Livtencity on 2021-11-23. It has been approved in Europe to treat cytomegalovirus infections.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
Trade Name
FDA
EMA
Livtencity
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Maribavir
Tradename
Company
Number
Date
Products
LIVTENCITYTakedaN-215596 RX2021-11-23
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
livtencityNew Drug Application2021-11-30
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
MARIBAVIR, LIVTENCITY, TAKEDA PHARMS USA
2028-11-23ODE-388
2026-11-23NCE
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AX: Other antivirals in atc
— J05AX10: Maribavir
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cytomegalovirus infectionsD003586EFO_0001062B25112——4
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—3————3
Hiv infectionsD015658EFO_0000764B201————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMARIBAVIR
INNmaribavir
Description
Maribavir, sold under the brand name Livtencity, is an antiviral medication that is used to treat post-transplant cytomegalovirus (CMV). Maribavir is a cytomegalovirus pUL97 kinase inhibitor that works by preventing the activity of human cytomegalovirus enzyme pUL97, thus blocking virus replication.
Classification
Small molecule
Drug classantivirals
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O
Identifiers
PDB—
CAS-ID176161-24-3
RxCUI—
ChEMBL IDCHEMBL515408
ChEBI ID—
PubChem CID471161
DrugBankDB06234
UNII IDPTB4X93HE1 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 692 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
77 adverse events reported
View more details